OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.

Press releases

16. April 2015

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius Biocapital II S.A. SICAR, acting as lead; a SMS Group Company; VC Fonds Technologie Berlin; High-Tech Gruenderfonds (HTGF); and KfW Group. As part of the financing round, the company has
12. December 2013

OMEICOS Therapeutics: Novel therapy for the treatment of atrial fibrillation

Our heart beats 60 to 100 times per minute, around 42 million times per year. Disturbances of the heart’s rhythm – so called arrhythmia- occur frequently, in particular in older people. Atrial fibrillation, the most common type of arrhythmia, typically represents with irregular palpitations, often associated with shortness of breath and anxiety attacks. Today, around 5-10 million patients in Europe suffer from atrial fibrillation and this number will further increase due to the demographic d

Info & Contact

Robert Fischer


Robert-Rössle-Straße 10
13125 Berlin

In portfolio

17. Sep 2013

Ulrike Kalapis

Investment Manager